About 4DMT
4DMT is a company based in Emeryville (United States) founded in 2013. It operates as a HealthTech. 4DMT has raised $186.59 million across 6 funding rounds from investors including Pfizer, Mirae Asset and Janus Henderson Investors. The company has 227 employees as of December 31, 2024. 4DMT offers products and services including 4D-150 and 4D-710. 4DMT operates in a competitive market with competitors including Kriya Therapeutics, Rezolute, Aviceda Therapeutics, EyePoint Pharmaceuticals and Molecular Partners, among others.
- Headquarter Emeryville, United States
- Employees 227 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name 4D Molecular Therapeutics, Inc.
-
Annual Revenue
$37 K-99.82as on Dec 31, 2024
-
Net Profit
$-160.87 M-59.53as on Dec 31, 2024
-
EBITDA
$-181.14 M-69.1as on Dec 31, 2024
-
Total Equity Funding
$186.59 M (USD)
in 6 rounds
-
Latest Funding Round
$75 M (USD), Series C
Jun 16, 2020
-
Investors
Pfizer
& 19 more
-
Employee Count
227
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of 4DMT
4DMT is a publicly listed company on the NASDAQ with ticker symbol FDMT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of 4DMT
4DMT offers a comprehensive portfolio of products and services, including 4D-150 and 4D-710. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Gene therapy developed for treating eye diseases effectively.
Gene therapy created for cystic fibrosis treatment solutions.
Funding Insights of 4DMT
4DMT has successfully raised a total of $186.59M across 6 strategic funding rounds. The most recent funding activity was a Series C round of $75 million completed in June 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Series C — $75.0M
-
First Round
First Round
(12 Aug 2015)
- Investors Count 20
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2020 | Amount | Series C - 4DMT | Valuation | Viking Global Investors | |
| Sep, 2018 | Amount | Series B - 4DMT | Valuation | Viking Global Investors | |
| Sep, 2017 | Amount | Series A - 4DMT | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in 4DMT
4DMT has secured backing from 20 investors, including venture fund and institutional investors. Prominent investors backing the company include Pfizer, Mirae Asset and Janus Henderson Investors. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private investment firm focused on multiple sectors
|
Founded Year | Domain | Location | |
|
Investing in Life Sciences sectors like Healthcare and Biotechnology.
|
Founded Year | Domain | Location | |
|
Support is provided for longevity breakthrough initiatives by Longevity Vision Holding.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by 4DMT
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - 4DMT
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
4Dmt Comparisons
Competitors of 4DMT
4DMT operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Kriya Therapeutics, Rezolute, Aviceda Therapeutics, EyePoint Pharmaceuticals and Molecular Partners, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| domain | founded_year | HQ Location |
Therapies for metabolic and orphan diseases are developed by Rezolute.
|
|
| domain | founded_year | HQ Location |
Biotherapeutics for glycol-immune diseases are developed across multiple therapeutic areas.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for ophthalmic disorders are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutic solutions for diseases are developed using DARPin technology.
|
|
| domain | founded_year | HQ Location |
mRNA-based therapeutics against cancer and infectious diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on 4Dmt
Frequently Asked Questions about 4DMT
When was 4DMT founded?
4DMT was founded in 2013 and raised its 1st funding round 2 years after it was founded.
Where is 4DMT located?
4DMT is headquartered in Emeryville, United States. It is registered at Emeryville, California, United States.
Is 4DMT a funded company?
4DMT is a funded company, having raised a total of $186.59M across 6 funding rounds to date. The company's 1st funding round was a Series A of $3M, raised on Aug 12, 2015.
How many employees does 4DMT have?
As of Dec 31, 2024, the latest employee count at 4DMT is 227.
What is the annual revenue of 4DMT?
Annual revenue of 4DMT is $37K as on Dec 31, 2024.
What does 4DMT do?
Genetic medicines are innovated by 4DMT using a proprietary vector platform for large market diseases. Focus is placed on ophthalmology, pulmonology, and cardiology sectors. Customized vectors are optimized for specific diseases, aiming for curative intent. Partnerships with patient organizations are maintained to address unmet needs. Continuous improvement of products is pursued to benefit patients significantly.
Who are the top competitors of 4DMT?
4DMT's top competitors include MeiraGTx, EyePoint Pharmaceuticals and Rezolute.
What products or services does 4DMT offer?
4DMT offers 4D-150 and 4D-710.
Is 4DMT publicly traded?
Yes, 4DMT is publicly traded on NASDAQ under the ticker symbol FDMT.
Who are 4DMT's investors?
4DMT has 20 investors. Key investors include Pfizer, Mirae Asset, Janus Henderson Investors, Cystic Fibrosis Foundation, and Perceptive Advisors.
What is 4DMT's ticker symbol?
The ticker symbol of 4DMT is FDMT on NASDAQ.